Efficacy of artemisinin-based combination therapy (ACT) in people living with HIV (PLHIV) diagnosed with uncomplicated Plasmodium falciparum malaria in Africa: a WWARN systematic review

Table 7 Effect of various ART regimens on DHA and artemether concentration levels, measured after the last AL dose

	Ratio (95% CI) of the geometric mean for PLHIV on various ART regimens to the geometric mean for HIV-uninfected patients
	EFV*	NVP**	LPV/r***
Artemether AUC_0–8	0.43 (0.30–0.62)^a	0.34 (0.25–0.46)^e	0.75 (0.53–1.05)
Artemether C_max	0.46 (0.30–0.69)^b	0.34 (0.23–0.45)^f	0.75 (0.50–1.11)
DHA AUC_0–8	0.37 (0.28–0.51)^c	0.70 (0.55–0.88)^g	0.81 (0.59–1.10)
DHA C_max	0.40 (0.28–0.58)^d	0.66 (0.50–0.87)^h	0.83 (0.57–1.19)

ART antiretroviral therapies, AUC area under the curve (from 0 to 8 h), CI confidence interval (95%), C_max maximum concentration, DHA dihydroartemisinin, EFV efavirenz, LPV/r lopinavir/ritonavir, CI confidence interval, PLHIV people living with HIV
^*shows results for the combined studies (ID 11, ID 15)
^**shows results for the combined studies (ID 1, ID 11)
^***shows results from study ID 11
^aI-squared = 0.0%, p-value for heterogeneity = 0.150
^bI-squared = 0.0%, p-value for heterogeneity = 0.474
^cI-squared = 81.0%, p-value of heterogeneity = 0.022
^dI-squared = 0.0%, p-value for heterogeneity = 0.322
^eI-squared = 51.7%, p-value for heterogeneity = 0.150
^fI-squared = 43.0%, p-value for heterogeneity = 0.185
^gI-squared = 0.0%, p-value of heterogeneity = 0.445
^hI-squared = 0.0%, p-value for heterogeneity = 0.842

ISSN: 1475-2875